stockportfolio.pro
Stocks / IBRX vs RGEN
IBRX vs RGEN
ImmunityBio, Inc. and Repligen Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ImmunityBio, Inc. (IBRX) | Repligen Corporation (RGEN) | |
|---|---|---|
| Market cap | $7.5B | $7.4B |
| Revenue (latest FY) | $113.29M | $738.26M |
| Net income (latest FY) | $-351.40M | $48.89M |
| Revenue growth (5y CAGR) | 184.8% | 15.0% |
| Net margin | -310.2% | 6.6% |
| Return on equity | 70.2% | 2.3% |
| P/E ratio | — | 144.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IBRX — free Open RGEN — freeFrequently asked questions
Which is bigger, IBRX or RGEN?
ImmunityBio, Inc. is larger by market capitalization — $7.5B versus $7.4B.
Which grows faster, IBRX or RGEN?
Over the last five fiscal years, ImmunityBio, Inc. grew revenue faster — 184.8%/yr versus 15.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.